Surgery Partners, Inc.

NasdaqGS:SGRY Stock Report

Market Cap: US$2.7b

Surgery Partners Past Earnings Performance

Past criteria checks 0/6

Surgery Partners has been growing earnings at an average annual rate of 37.5%, while the Healthcare industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 11.2% per year.

Key information

37.5%

Earnings growth rate

52.5%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate11.2%
Return on equity3.0%
Net Margin-2.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower

Dec 08
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Oct 26
Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Sep 17
Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

Aug 26
Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Jul 21
The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

Jun 15
Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

May 26
A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Apr 14
There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Mar 24
Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 24
Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

Sep 26
We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Aug 15
The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Surgery Partners GAAP EPS of -$0.21 misses by $0.07, revenue of $615.4M misses by $3.61M

Aug 02

Surgery Partners And Alternative Near Cap-Gain Portfolio Wealth Builders

Jul 02

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Jun 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Revenue & Expenses Breakdown

How Surgery Partners makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SGRY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,985-611240
30 Jun 242,889-341310
31 Mar 242,79511220
31 Dec 232,743-121210
30 Sep 232,715-341290
30 Jun 232,662-541100
31 Mar 232,609-921050
31 Dec 222,539-551020
30 Sep 222,442-311010
30 Jun 222,381-291080
31 Mar 222,309-381070
31 Dec 212,225-811040
30 Sep 212,163-861010
30 Jun 212,100-1351000
31 Mar 211,932-1501010
31 Dec 201,860-156970
30 Sep 201,829-179970
30 Jun 201,785-132920
31 Mar 201,856-119900
31 Dec 191,831-110890
30 Sep 191,805-238870
30 Jun 191,786-243870
31 Mar 191,777-241900
31 Dec 181,772-238940
30 Sep 181,732-122840
30 Jun 181,597-125890
31 Mar 181,443-102790
31 Dec 171,312-79690
30 Sep 171,159-22710
30 Jun 171,1357600
31 Mar 171,13914560
31 Dec 161,1219550
30 Sep 161,0799600
30 Jun 161,0399580
31 Mar 169811560
31 Dec 159361560
30 Sep 15855-70460
30 Jun 15696-73420
31 Mar 15544-69360
31 Dec 14394-66310

Quality Earnings: SGRY is currently unprofitable.

Growing Profit Margin: SGRY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SGRY is unprofitable, but has reduced losses over the past 5 years at a rate of 37.5% per year.

Accelerating Growth: Unable to compare SGRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGRY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.4%).


Return on Equity

High ROE: SGRY has a negative Return on Equity (2.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 05:43
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Surgery Partners, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Steven ValiquetteBarclays
Sarah JamesBarclays
Andrew MokBarclays